drugset / Trial / NCT03903822
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the dose and dosing regimen (once daily \[QD\] vs twice daily \[BID\] application) for the future clinical development of topical PF-06700841.
Timeline
- Start
- 2019-05-13
- Primary completion
- 2020-05-07
- Completion
- 2020-05-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brepocitinib | Small molecule | 0.1 % | Topical |
| Subject | Brepocitinib | Small molecule | 0.3 % | Topical |
| Subject | Brepocitinib | Small molecule | 1 % | Topical |
| Subject | Brepocitinib | Small molecule | 3 % | Topical |